The Best of Canadian Science and Technology
The cannabis space has seen more than its share of ups and downs in recent years but for those looking to jump in, there’s probably no better place to … [Read more...] about Canopy Growth is the one pot stock to own, this fund manager says
After quarterly results for Canadian movie theatre company Cineplex (Cineplex Stock Quote, Chart, News TSX:CGX), analyst Rob Goff of Echelon Wealth is … [Read more...] about Cineplex faced with “significant uncertainty”, Echelon Wealth says
Microcap cannabis company Heritage Cannabis (Heritage Cannabis Stock Quote, Chart, News CSE:CANN) received a major target drop from PI Financial’s … [Read more...] about Heritage Cannabis is still a buy, says PI Financial
Investors should still be in a wait-and-see mode when it comes to Canadian tech company BlackBerry (TSX:BB). That’s according to RBC Capital analyst … [Read more...] about BlackBerry is a pass, says RBC
Echelon Wealth Partners analyst Douglas Loe is staying bullish on cardiovascular drug developer Acasti Pharma (Acasti Pharma Stock Quote, Chart, News … [Read more...] about Buy Acasti Pharma for a double, Echelon says
Canadian telecom stocks are having trouble getting back to where they were before COVID-19 struck, but there are good long-term prospects in a name … [Read more...] about BCE is a good place to put your money now, this fund manager says
Beacon Securities analyst Ahmad Shaath says the new contract wins by Greenlane Renewables (Greenlane Renewables Stock Quote, Chart, News TSXV:GRN) are … [Read more...] about Greenlane Renewables gets bullish new price target at Beacon Securities
Shopify (Shopify Stock Quote, Chart, News TSX:SHOP) is firing on all cylinders during COVID-19 and while the stars are aligning well for the Canadian … [Read more...] about Shopify’s move into logistics is a gamble, Paul Harris says
Raymond James analyst Rahul Sarugaser has dropped his rating on Canadian cannabis LP Organigram Holdings (Organigram Holdings Stock Quote, Chart, News … [Read more...] about Organigram has price target chopped at Raymond James
Stifel GMP analyst Justin Keywood says that COVID-19 is presenting both challenges and opportunities for ATS Automation Tooling Systems (ATS … [Read more...] about Stifel explains why ATS Automation is a buy
